Browsing by Author "Boz Er, Asiye Büşra"
Now showing items 1-7 of 7
-
The correlation between brafv600e expression and integrin β3 in melanoma cells
Er, İdris; Boz Er, Asiye Büşra (Academic Publishing House, 2024)This study investigated the relationship between ITGB3 and BRAFV600E expression in melanoma. It specifically focused on how the overexpression of BRAFV600E and Integrin β3 impacts wound healing and the TGF-β pathway. The ... -
Hedgehog pathway is a regulator of stemness in HER2-positive trastuzumab-resistant breast cancer
Er, İdris; Boz Er, Asiye Büşra (MDPI, 2024)HER2 overexpression occurs in 20–30% of breast cancers and is associated with poor prognosis. Trastuzumab is a standard treatment for HER2-positive breast cancer; however, resistance develops in approximately 50% of patients ... -
Integrin β3 reprogramming stemness in HER2-positive breast cancer cell lines
Boz Er, Asiye Büşra (MDPI, 2024)HER2-positive breast cancer, characterised by overexpressed HER2 levels, is associated with aggressive tumour behaviour and poor prognosis. Trastuzumab is a standard treatment; however, approximately 50% of patients develop ... -
Investigation of ITGB3 heterogeneity to overcome trastuzumab resistance in HER2-positive breast cancer
Boz Er, Asiye Büşra (MDPI, 2025)HER2-positive breast cancer has an aggressive tumour progression among breast cancers characterized by the overexpression of HER2. Trastuzumab is an FDA-approved drug and has significantly improved outcomes for patients; ... -
Notch and hedgehog signalling axis drive senescence in HER2-positive breast cancer resistant to trastuzumab
Boz Er, Asiye Büşra; Er, İdris (Istanbul University Press, 2024)Objective: Cellular senescence halts the proliferation of damaged or preneoplastic cells, playing a vital role in cancer control. In HER2-positive breast cancer, resistance to trastuzumab, a HER2-targeted monoclonal antibody, ... -
PAI1 regulates cell morphology and migration markers in trastuzumab-resistant HER2-positive breast cancer cells
Boz Er, Asiye Büşra; Er, İdris (Multidisciplinary Digital Publishing Institute (MDPI), 2024)HER2-positive breast cancer is a significant cause of mortality. Overcoming trastuzumab resistance requires a deeper understanding of its molecular mechanisms to develop effective therapies. This study investigates the ... -
Targeting ITGβ3 to overcome trastuzumab resistance through epithelial–mesenchymal transition regulation in HER2-positive breast cancer
Boz Er, Asiye Büşra; Er, İdris (MDPI, 2024)HER2-positive breast cancer, representing 15–20% of all breast cancer cases, often develops resistance to the HER2-targeted therapy trastuzumab. Unfortunately, effective treatments for advanced HER2-positive breast cancer ...